MA54619A - Cristal de composé d'acide pyrophosphorique - Google Patents

Cristal de composé d'acide pyrophosphorique

Info

Publication number
MA54619A
MA54619A MA054619A MA54619A MA54619A MA 54619 A MA54619 A MA 54619A MA 054619 A MA054619 A MA 054619A MA 54619 A MA54619 A MA 54619A MA 54619 A MA54619 A MA 54619A
Authority
MA
Morocco
Prior art keywords
acid compound
pyrophosphoric acid
compound crystal
crystal
pyrophosphoric
Prior art date
Application number
MA054619A
Other languages
English (en)
Inventor
Hiroomi Nagata
Naoko Ueda
Takahiro Yoshida
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MA54619A publication Critical patent/MA54619A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA054619A 2018-12-28 2019-12-27 Cristal de composé d'acide pyrophosphorique MA54619A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018247437 2018-12-28

Publications (1)

Publication Number Publication Date
MA54619A true MA54619A (fr) 2021-11-03

Family

ID=71127176

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054619A MA54619A (fr) 2018-12-28 2019-12-27 Cristal de composé d'acide pyrophosphorique

Country Status (8)

Country Link
US (2) US12077524B2 (fr)
EP (3) EP4603143A3 (fr)
JP (3) JP6977185B2 (fr)
CN (3) CN113226314B (fr)
ES (1) ES2991904T3 (fr)
MA (1) MA54619A (fr)
TW (2) TWI870228B (fr)
WO (1) WO2020138481A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230016008A (ko) 2020-06-10 2023-01-31 미쓰비시 타나베 파마 코퍼레이션 광선성 피부질환의 예방 또는 치료제
CA3186880A1 (fr) 2020-06-10 2021-12-16 Mitsubishi Tanabe Pharma Corporation Agent prophylactique ou therapeutique de traitement de la porphyrie
WO2021251450A1 (fr) 2020-06-10 2021-12-16 田辺三菱製薬株式会社 Agent prophylactique ou thérapeutique de traitement de la porphyrie
MX2023013044A (es) * 2021-05-06 2023-11-15 Lg Chemical Ltd Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma.
BR112023022863A2 (pt) * 2021-05-06 2024-01-23 Lg Chemical Ltd Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo
US20240239769A1 (en) * 2021-05-07 2024-07-18 Lg Chem, Ltd. Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same
EP4317148A4 (fr) * 2021-05-07 2024-09-18 Lg Chem, Ltd. Cristaux de sulfate de composé agoniste du récepteur de la mélanocortine et leur procédé de production
AU2022271120A1 (en) * 2021-05-07 2023-11-09 Lg Chem, Ltd. Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof
AU2023213357A1 (en) 2022-01-31 2024-08-15 Mitsubishi Tanabe Pharma Corporation Novel use of melanocortin-1 receptor agonist
CN119654150A (zh) 2022-08-03 2025-03-18 田边三菱制药株式会社 含有1-｛2-[（3s,4r）-1-｛[（3r,4r）-1-环戊基-3-氟-4-（4-甲氧基苯基）吡咯烷-3-基]羰基｝-4-（甲氧基甲基）吡咯烷-3-基]-5-（三氟甲基）苯基｝哌啶-4-甲酸或其药学上可接受的盐或者共晶的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143404B2 (en) 2004-09-13 2012-03-27 Ono Pharmaceutical Co., Ltd Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
CN101365476A (zh) * 2005-10-07 2009-02-11 瓦拉塔药品公司 Dpp-iv抑制剂和胃泌素化合物的联合使用
PL3150578T3 (pl) * 2014-05-29 2021-07-19 Mitsubishi Tanabe Pharma Corporation Nowy związek pirolidynowy i zastosowanie jako agonisty receptora melanokortyny
JP6392297B2 (ja) * 2015-11-27 2018-09-19 田辺三菱製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
EP4603143A2 (fr) 2025-08-20
US20250002474A1 (en) 2025-01-02
CN120081826A (zh) 2025-06-03
CN113226314B (zh) 2025-03-18
CN120081827A (zh) 2025-06-03
ES2991904T3 (es) 2024-12-05
JP2025085744A (ja) 2025-06-05
EP3903785A4 (fr) 2022-08-10
EP3903785B1 (fr) 2024-10-02
CN113226314A (zh) 2021-08-06
TW202039464A (zh) 2020-11-01
EP4434582A2 (fr) 2024-09-25
JP6977185B2 (ja) 2021-12-08
TWI870228B (zh) 2025-01-11
TWI834791B (zh) 2024-03-11
US12077524B2 (en) 2024-09-03
EP4603143A3 (fr) 2025-11-05
US20220073497A1 (en) 2022-03-10
TW202421621A (zh) 2024-06-01
JP2022024034A (ja) 2022-02-08
EP4434582A3 (fr) 2024-12-18
EP3903785A1 (fr) 2021-11-03
TW202517631A (zh) 2025-05-01
JP7652682B2 (ja) 2025-03-27
WO2020138481A1 (fr) 2020-07-02
JPWO2020138481A1 (ja) 2021-09-27

Similar Documents

Publication Publication Date Title
EP3903785A4 (fr) Cristal de composé d'acide pyrophosphorique
PL3838888T3 (pl) Triestry kwasu cykloheksanotripropionowego
EP4083038A4 (fr) Composé pyridazinyl thiazolecarboxamide
EP3473626A4 (fr) Cristal de pyrrolopyrimidine pour la préparation d'un inhibiteur jak
MA42615A (fr) Composés phosphodiamide antiviraux d'ester d'acide bêta-aminé
MA52877A (fr) Acide hyaluronique stabilisé
EP3808783A4 (fr) Nouvel acide alginique réticulé
EP3612152A4 (fr) Administration topique de composés d'acide nucléique
FIC20260011I1 (fi) nirogasestaatin dihydrobromidisuolan kiteinen muoto
DK3784649T3 (da) Fremgangsmåde til syntese af (s)-3-amino-4-(difluormethylenyl)cyclopent-1-en-1-carboxylsyre
EP3930877C0 (fr) Production de dialysat usagé concentré
EP3808747A4 (fr) Composé d'imidazopyridinone
IL280902A (en) Compounds useful as chaperone-mediated autophagy modulators
EP4003323A4 (fr) Formulations stabilisées de dérivés de l'acide butanoïque du type 4-amino-3-substitués
PL3976591T3 (pl) Sposoby wytwarzania kwasu 5-bromo-2-(3-chloropirydyn-2-ylo)-2h- pirazolo-3-karboksylowego
JOP20200030A1 (ar) مركب خماسي الحلقة
HUE063674T2 (hu) Eljárás N-(amino-imino-metil)-2-aminoetánsav (III) metastabil kristálymódosulatának elõállítására
DK3823952T3 (da) Oprensning af levulinsyre
EP3670630C0 (fr) Nouvelles compositions d'acide alkylsulfonique
DK3777858T3 (da) Middel til at hæmme stigning af intraneuronal calciumkoncentration
IL280441A (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
MA49704A (fr) Dérivés d'acide biliaire à marquage isotopique
PT3845524T (pt) Compostos de ácido benzoico e método de preparação destes e suas aplicações
DK3599243T3 (da) 17beta-heterocyklyl-digitalis-lignende forbindelser til behandlingen af hjertesvigt
EP3919493A4 (fr) Cristal d'un composé diarylthiohydantoïne